More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics
Molecular Oncology · 2023
DOI: 10.1002/1878-0261.13391 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Oncology, 2023. Verfasst von René Bernards. Beteiligte Einrichtung: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The advent of a new generation of targeted cancer drugs requires a radically different design of early clinical trials. Here, René Bernards discusses why new clinical trial designs are needed and what is being done to achieve this. Such innovative trials can lead to similar outcomes for cancer patients with fewer side effects while at the same time reducing the cost of cancer care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
ORCID-Profile: René Bernards
Zitieren
APA
Bernards, R. (2023). More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics. Molecular Oncology. https://doi.org/10.1002/1878-0261.13391
Vancouver
Bernards R. More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics. Molecular Oncology. 2023. doi:10.1002/1878-0261.13391
BibTeX
@article{Bernards2023,
author = {Bernards, René},
title = {More may not be better: reconsidering early clinical trial design in the era of targeted cancer therapeutics},
journal = {Molecular Oncology},
year = {2023},
doi = {10.1002/1878-0261.13391}
}
EUVIMED